A Phase 1b Study of MEDI4736 in Combination with Tremelimumab in Subjects with Advanced Non-Small Cell Lung Cancer

Full Title

A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects with Advanced Non-Small Cell Lung Cancer

Purpose

This study is a multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic, immunogenicity, and antitumor activity of MEDI4736 in combination with tremelimumab in adult subjects with advanced NSCLC.

MEDI4736 is an anti-PD-L1 monoclonal antibody. Tremelimumab is an anti-CTLA4 monoclonal antibody. Both are given by intravenous infusion.

Eligibility

To be eligible for this study, patients must:

  • Have advanced non-small cell lung cancer
  • Have an ECOG status of 0 or 1.
  • Be age 18 or older.

For more information about this study and to inquire about eligibility, please contact Dr. Jamie Chaft at 646-888-4545.

Protocol

13-197

Phase

I

Investigator

Co-Investigators

Locations